MetLife, Inc. (MET) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is mixed — a pre-announced variable investment income (VII) shortfall of ~$220–270M (vs. ~$400M quarterly run rate) is the known headwind, but the bar on Group Benefits underwriting and the broader earnings base is achievable, leaving the print directionally in-line with a modest downside skew on EPS unless mortality and disability surprise favorably.

MetLife heads into Q2 2026 with a well-telegraphed drag: the company pre-announced on June 29 that variable investment income would come in at $220–270M pre-tax — well below the ~$400M quarterly run rate guided at the start of the year and a sharp step-down from the $518M delivered in Q1 2026. This is the single biggest swing factor for the quarter, as VII flows directly into adjusted EPS and is concentrated in the RIS and Corporate segments. On the underwriting side, peer read-throughs from Lincoln Financial and Unum are constructive: both reported continued favorable group life mortality in Q2 (LNC's life loss ratio improved ~500bps YoY; UNM's group life benefit ratio was 66%), while disability results showed modest normalization — PFML headwinds were significantly smaller in Q2 vs. Q1 for LNC (~20bps vs. ~100bps). Management's tone at the June Morgan Stanley conference was confident on Latin America's $1B earnings target, MIM integration, and Asia momentum, while explicitly flagging Q2 VII pressure and range-bound RIS spreads. Consensus EPS for Q2 2026 stands at $2.30 (vs. $2.42 actual in Q1 2026 and $2.02 actual in Q2 2025), implying ~14% YoY growth — a bar that looks achievable on the underwriting side but faces a real headwind from the VII pre-announcement. The stock has rallied ~20% since the Q1 print, outperforming both the insurance ETF (KIE, +15%) and the S&P 500 (+5%), suggesting the market has already priced in a solid fundamental story; the wildcard is whether mortality and disability come in clean enough to offset the VII miss and allow management to hold the full-year VII guidance of ~$1.6B.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus EPS of $2.30 is a moderate bar given the pre-announced VII shortfall; the bigger swing factor is Group Benefits underwriting — if mortality stays favorable and disability normalizes as expected, the segment can offset much of the VII drag.

Table 1 — Q2 2026 Snapshot (Key KPIs)

Source: Visible Alpha consensus and actuals data. All consensus figures as of latest available (August 4, 2026). VII Q2 2026 consensus reflects pre-announcement range midpoint.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Adj. EPS (Diluted, Operating)

Group Life Mortality Ratio (%)

Pattern: MET has beaten on adjusted EPS in 4 of the last 8 quarters, with the two most recent quarters (Q4 2025, Q1 2026) both delivering meaningful beats driven by above-expectation VII and favorable mortality. On mortality, MET has beaten consensus (i.e., reported a lower-than-expected ratio) in 6 of the last 8 quarters, reflecting a sustained favorable working-age mortality trend — the key question for Q2 is whether this streak continues given peer read-throughs suggest it does.

Source: Visible Alpha consensus and actuals data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been materially revised on one item since Q1 earnings — Q2 VII was pre-announced at $220–270M vs. the ~$400M quarterly run rate — while tone on mortality, Latin America, and MIM integration has become more constructive; disability severity remains a watch item.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: EPS estimates for Q2 2026 have been revised down ~3.9% since the Q1 print (from $2.39 to $2.30), almost entirely driven by the VII pre-announcement; FY 2026 EPS estimates are essentially flat, suggesting the market views the Q2 VII shortfall as a timing issue rather than a structural impairment.

The VII pre-announcement drove the bulk of Q2 EPS estimate cuts (~$0.09/share), while FY 2026 EPS estimates are nearly flat, implying the street expects Q3 VII to recover (consistent with management's constructive Q3 commentary at the June MS conference). Mortality estimates have actually been revised slightly more favorable since the Q1 print, reflecting the sustained working-age mortality trend. The key risk is whether the FY VII guidance of ~$1.6B is achievable given Q2 came in at the low end of the pre-announced range.

Source: Visible Alpha consensus and actuals data. Baseline as of May 13, 2026 (5 trading days post Q1 earnings).

5. Stock Performance

Key Takeaway: MET has rallied ~20% since the Q1 2026 earnings date (May 6), sharply outperforming both the insurance sector ETF (KIE, +15%) and the S&P 500 (+5%), driven by a combination of estimate revisions, multiple re-rating, and the constructive June Morgan Stanley conference; the stock is no longer cheap on a relative basis, raising the bar for a positive Q2 reaction.

MET vs. KIE (Insurance ETF) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings Date (May 6, 2026). Source: Stock Price Data.

MET's outperformance since the Q1 print has been broad-based and durable. The stock initially dipped ~3% in the first week post-earnings (likely reflecting the muted reaction to an in-line-with-elevated-expectations print), then re-rated sharply higher through May and June, accelerating around the June 9–12 period coinciding with the Morgan Stanley US Financials Conference where CFO McCallion provided constructive commentary on Latin America, MIM, and Asia. The VII pre-announcement on June 29 caused only a brief pause, with the stock recovering quickly as investors appeared to view the Q2 shortfall as transitory. The stock has continued to grind higher into July, reaching ~$97 by late July. At current levels (~$96), MET trades at approximately 9.7x NTM consensus EPS — still at a discount to historical averages but meaningfully above the trough multiple, suggesting the market has already priced in a significant portion of the New Frontier re-rating story. The sector ETF (KIE) has also performed well (+15%), reflecting broad insurance sector strength, while the S&P 500 has lagged (+5%), making MET's alpha generation particularly notable.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the June 29 pre-announcement of Q2 VII at $220–270M — well below the ~$400M run rate — which is the primary known headwind into the print; all other developments (MS conference, annual meeting, dividend declaration) are constructive or neutral.

• June 29, 2026 — MetLife Pre-Announces Q2 2026 Variable Investment Income (8-K): MetLife disclosed preliminary Q2 VII of approximately $220–270M pre-tax, compared to the ~$400M quarterly run rate guided at the start of the year and $518M in Q1 2026. Full-year 2026 VII guidance of ~$1.6B was maintained. Implication: This is the single biggest known headwind into the Q2 print; the pre-announcement removes uncertainty on VII but creates a ~$130–180M pre-tax shortfall vs. run rate. The market's muted reaction to the 8-K suggests investors view this as transitory, consistent with management's constructive Q3 commentary.
• June 10, 2026 — CFO McCallion at Morgan Stanley US Financials Conference: CFO John McCallion provided detailed forward-looking commentary across all segments. Key highlights: Latin America $1B earnings target characterized as ‘real for ’26’; Accelerator platform grew from $200M to $700M in sales in ~1 year; MIM integration progressing better than anticipated; Q3 VII setup described as constructive given market recovery, IPO activity, and VC portfolio positioning; private fixed income portfolio predominantly investment grade with no BDC exposure; AI driving meaningful productivity gains (higher claims auto-adjudication rates, multiple-fold increase in RFP output capacity). Implication: Broadly constructive; reinforced the New Frontier narrative and provided incremental confidence on LatAm and MIM.
• June 22, 2026 — Annual Shareholder Meeting (8-K): Shareholders affirmed governance and compensation at the 2026 Annual Meeting. No material governance changes. Implication: Neutral; routine governance event.
• May 15, 2026 — Quarterly Preferred Stock Dividend Declaration (8-K): MetLife declared quarterly dividends on preferred stock series. Implication: Neutral; routine capital action.
• May 6, 2026 — Q1 2026 Earnings (Reference Point): Adjusted EPS of $2.42 (+18% YoY), adjusted ROE of 17% (top of 15–17% target range), direct expense ratio of 11.9% (below 12.1% full-year target). All six segments grew earnings YoY. VII of $518M was the third consecutive above-expectation quarter. Group Life mortality ratio of 80.1% was well below the 83–88% target range. Non-medical health benefit ratio of 75.8% was above the 70–75% target due to dental seasonality, PFML, and elevated LTD severity. Implication: Sets a high bar for Q2 on most metrics except VII, which is already known to be a headwind.
• Ongoing — Japan FSA Regulatory Matter: MetLife Japan is navigating an industry-wide FSA regulatory matter involving improper data extraction by seconded employees at partner agencies. Management has characterized it as an industry-wide change in practice with no observed impact on business results or sales. Implication: Watch item; management's characterization as non-material has been consistent, but any escalation would be a negative surprise.
• Ongoing — No Analyst Rating Changes Since Q1 Earnings: No upgrades or downgrades were identified in the period since the Q1 2026 earnings release. Implication: Neutral; the absence of rating changes suggests the sell-side is broadly comfortable with the current setup.

7. Peer Commentaries — Q2 2026 Read-Throughs (Last 60 Days)

Key Takeaway: Peer Q2 2026 earnings from Lincoln Financial (LNC) and Unum (UNM) are broadly constructive for MET's Group Benefits segment — both reported continued favorable group life mortality and a meaningful easing of PFML headwinds vs. Q1, though disability results showed modest normalization; LNC's alternative investment returns were weak, a potential read-through for MET's VII.

Note: Only peer commentary from Q2 2026 earnings calls (reporting on the current quarter) is included below. Q1 2026 earnings calls from peers (reporting on prior quarter results) are excluded per the user's instruction. Peers included: Lincoln Financial (LNC, reported July 30, 2026) and Unum Group (UNM, reported July 29, 2026).

Lincoln Financial (LNC) — Q2 2026 Earnings (Reported July 30, 2026)

Group Life Mortality — Strongly Favorable; Broad-Based Improvement

Read-Through for MET: LNC reported a Group Protection life loss ratio of approximately 62% in Q2 2026, improving roughly 500 basis points year-over-year, driven by “low incidence levels” supporting favorable mortality. In the Life Insurance segment, LNC described mortality as “among the most favorable results we have seen in some time,” with broad-based favorability across both frequency and severity, consistent with broader improvements in U.S. mortality trends. LNC noted that 5 of the last 6 quarters have been favorable for mortality, mostly in the term block. Management flagged that while Q3 typically sees a seasonal improvement from Q2, Q2’s favorability was greater than the typical seasonal uplift, suggesting some caution about the magnitude of Q3 improvement. MET implication: Strongly positive read-through for MET’s Group Life mortality ratio in Q2 2026. Consensus expects MET’s mortality ratio at 82.6% — LNC’s data suggests the favorable working-age mortality trend that drove MET’s 80.1% in Q1 likely continued into Q2, potentially setting up another beat vs. the 82–83% consensus.

Disability / PFML — Meaningful Improvement vs. Q1; Normalization Continues

Read-Through for MET: LNC reported a disability loss ratio of 71.9% in Q2 2026, elevated vs. 64.2% a year ago but reflecting normalization from historically strong 2025 results. Critically, the PFML headwind to the disability loss ratio was approximately 20 basis points in Q2, compared to approximately 100 basis points in Q1 — a dramatic improvement. LNC noted that STD including PFML was “a little bit pressured” but the PFML headwind was “much less severe” in Q2 vs. Q1. LNC expects disability results to reflect a “broadly similar year-over-year headwind” for the remainder of 2026 as the benefit from strong 2025 experience continues to moderate. MET implication: Moderately positive read-through. MET’s Q1 non-medical health benefit ratio of 75.8% was above the 70–75% target, partly driven by PFML and elevated LTD severity. LNC’s data suggests PFML headwinds eased materially in Q2, which should help MET’s benefit ratio move back toward the target range. Consensus expects MET’s non-medical health benefit ratio at 74.3% in Q2 — achievable if PFML normalizes as LNC’s data suggests.

Alternative Investment Returns — Weak; Potential VII Read-Through

Read-Through for MET: LNC reported alternative investment returns of 4.9% annualized in Q2 2026 vs. a 10% target, representing an approximately $39M headwind to the Life Insurance segment. LNC expects alternative investment returns to recover and be at or above target in Q3. MET implication: Directionally negative read-through for MET’s VII, consistent with the pre-announced $220–270M range. LNC’s weak alternatives performance in Q2 corroborates the broader private equity/alternatives environment that drove MET’s VII shortfall. However, MET’s VII is more diversified (private equity, real estate, VC, prepayment fees) and skewed toward AI-focused VC, which may have performed differently.

Group Protection Margin — Within Target Range; Competitive Market Rational

Read-Through for MET: LNC’s Group Protection segment delivered operating income of $147M (vs. $173M a year ago), with a margin of 10.4% (down 210bps YoY). Excluding a $15M prior-year PFML experience refund, earnings declined $11M as life favorability was more than offset by modest disability normalization. LNC expects to deliver a full-year Group Protection margin within its 8–9% target range. The market was described as “competitive but rational.” Premium growth was 2.5% YoY, with supplemental health premium up 28% YoY. MET implication: Neutral to slightly positive. The competitive environment remains rational, which is supportive of MET’s Group Benefits pricing discipline and persistency (high-90s in national accounts). MET’s Group Benefits segment is larger and more diversified, and its Q1 2026 earnings of $439M (+19% YoY) suggest it is outperforming LNC on a relative basis.

Unum Group (UNM) — Q2 2026 Earnings (Reported July 29, 2026)

Group Life Mortality — Favorable; Sustainable at Current Levels

Read-Through for MET: UNM reported a group life and AD&D benefit ratio of 66% in Q2 2026, down from 69.7% in Q2 2025, driven by “continued lower incidents.” Management described this as reflecting “favorable mortality trends we’ve experienced recently consistent with the pattern observed over the last several quarters, which we do expect to continue.” UNM explicitly stated the 66% benefit ratio is “definitely sustainable” and does not expect to give away these margins through pricing. Adjusted operating income for group life and AD&D was $93.2M, up from $70.2M in Q2 2025. MET implication: Strongly positive read-through. UNM’s data corroborates LNC’s favorable mortality signal and reinforces the view that working-age mortality trends remained favorable in Q2 2026. This is the most important positive read-through for MET’s Group Benefits segment heading into the print.

Group Disability / PFML — Elevated but Improving; Pricing Actions Underway

Read-Through for MET: UNM’s group disability benefit ratio was 65.8% in Q2 2026, above the 62–64% expected range. PFML drove approximately 60–70% of the 2-point pressure on the benefit ratio. LTD recoveries remained consistent with expectations, and underlying LTD trends were stable. UNM has begun implementing double-digit rate adjustments for PFML new business and renewals, but expects the benefit ratio to remain elevated “more in line with the experience in the past 2 quarters” until new rates are fully embedded. UNM views 65% as the right sustainable long-term benefit ratio for group disability. MET implication: Mixed. PFML remains a headwind for the industry in Q2, though UNM’s data suggests it is manageable and improving. MET’s non-medical health benefit ratio was 75.8% in Q1 (above the 70–75% target); UNM’s experience suggests Q2 should see some improvement but the ratio may remain above the target range. The key difference is that MET has the ability to reprice ~50% of its disability book annually.

Overall Group Benefits Performance — Favorable Life Offsets Disability Pressure

Read-Through for MET: UNM’s total group benefits benefit ratio was 65.9% in Q2 2026 (vs. 65.2% in Q2 2025), with favorable group life mortality balancing increased PFML pressure in group disability. This translated to a combined ROE exceeding 25%. Core earned premium grew 3.6% YoY. Total U.S. group persistency was 91.5%, up nearly 2 percentage points YoY. UNM reaffirmed its full-year EPS outlook of $8.60–$8.90. MET implication: Positive read-through. The overall Group Benefits picture for the industry in Q2 is one of favorable life mortality offsetting modest disability normalization — exactly the dynamic that would allow MET’s Group Benefits segment to deliver solid earnings despite the VII headwind. UNM’s reaffirmation of full-year guidance is also a positive signal for industry fundamentals.

U.K. Group Income Protection — Elevated Claims; Watch Item for MET’s EMEA

Read-Through for MET: UNM International reported adjusted operating income of $24.3M in Q2 2026, down from $41.6M in Q2 2025, driven by unfavorable U.K. group income protection experience. The U.K. benefit ratio was 82.2% (vs. 75% a year ago), driven by a higher proportion of claims from high-income employees increasing average benefit costs. UNM expects pressure to continue in H2 but at a lower level, supported by pricing and underwriting actions. Larger price actions will take effect mostly in 2027 given 2–3 year rate guarantee periods in the U.K. market. MET implication: Modest watch item for MET’s EMEA segment, which has approximately two-thirds of earnings from Europe. However, MET’s EMEA business is more diversified (protection-oriented, A&H, life) and has been growing strongly (earnings up 33% in Q1 2026). The U.K. group income protection dynamic is more specific to UNM’s product mix.

Peer Read-Through Summary Table

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells were recorded since the Q1 2026 earnings date; all transactions are routine director compensation grants (code A) and one option exercise by the Chief Risk Officer — nothing that signals unusual conviction or concern from insiders.

No open-market buys (Form 4 code P) or discretionary open-market sells (Form 4 code S) were recorded for MET insiders in the period from May 6, 2026 through August 4, 2026. All transactions are routine director compensation grants (code A) awarded at the June 2026 annual meeting cycle, and one option exercise by the Chief Risk Officer. The absence of discretionary selling ahead of the Q2 print is a mild positive signal, though the absence of open-market buying means insiders are not adding conviction at current levels. No 10b5-1 plan initiations were identified in this period.

Source: SEC Form 4 Filings Database (Insider Transaction Data).